CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment	Total Varex Equity	Total Varex Equity Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Additional Paid-in Capital Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Noncontrolling Interests
Balance at beginning of period at Oct. 01, 2021	$ 496.5		$ 483.3		$ 0.4	$ 449.4		$ 0.0	$ 33.5		$ 13.2
Shares outstanding, beginning of period (in shares) at Oct. 01, 2021					39,400,000
Increase (Decrease) in Stockholders' Equity
Net (loss) income	30.8		30.3						30.3		0.5
Exercise of stock options	3.8		3.8			3.8
Exercise of stock options (in shares)					100,000
Common stock issued upon vesting of restricted shares (in shares)					400,000
Shares withheld on vesting of restricted shares	(2.8)		(2.8)			(2.8)
Shares withheld on vesting of restricted shares (in shares)					(100,000)
Common stock issued under employee stock purchase plan	4.9		4.9			4.9
Common stock issued under employee stock purchase plan (in shares)					300,000
Share-based compensation	14.0		14.0			14.0
Unrealized and realized loss (gain) on forward contracts	(0.6)		(0.6)					(0.6)
Unrealized loss (gain) on change in fair value of available-for-sale securities	(0.1)		(0.1)					(0.1)
Unrealized loss (gain) on defined benefit obligations, net of tax	1.4		1.4					1.4
Foreign currency translation adjustments	(0.6)		(0.6)					(0.6)
Other	(0.6)		(0.2)			(0.2)					(0.4)
Balance at ending of period at Sep. 30, 2022	$ 546.7	$ (28.5)	533.4	$ (28.5)	$ 0.4	469.1	$ (34.6)	0.1	63.8	$ 6.1	13.3
Shares outstanding, end of period (in shares) at Sep. 30, 2022					40,100,000
Increase (Decrease) in Stockholders' Equity
Accounting Standards Update [Extensible List]	Accounting Standards Update 2020-06
Net (loss) income	$ 48.7		48.2						48.2		0.5
Exercise of stock options	0.2		0.2			0.2
Common stock issued upon vesting of restricted shares (in shares)					200,000
Shares withheld on vesting of restricted shares	(1.4)		(1.4)			(1.4)
Shares withheld on vesting of restricted shares (in shares)					(100,000)
Common stock issued under employee stock purchase plan	3.9		3.9			3.9
Common stock issued under employee stock purchase plan (in shares)					300,000
Share-based compensation	13.5		13.5			13.5
Unrealized and realized loss (gain) on forward contracts	0.1		0.1					0.1
Unrealized loss (gain) on change in fair value of available-for-sale securities	0.1		0.1					0.1
Unrealized loss (gain) on defined benefit obligations, net of tax	(1.0)		(1.0)					(1.0)
Foreign currency translation adjustments	(0.5)		(0.5)					(0.5)
Other	(0.8)		(0.3)			(0.3)					(0.5)
Balance at ending of period at Sep. 29, 2023	$ 581.0		567.7		$ 0.4	450.4		(1.2)	118.1		13.3
Shares outstanding, end of period (in shares) at Sep. 29, 2023	40,529,573				40,500,000
Increase (Decrease) in Stockholders' Equity
Net (loss) income	$ (47.2)		(47.7)						(47.7)		0.5
Common stock issued upon vesting of restricted shares (in shares)					400,000
Shares withheld on vesting of restricted shares	(2.2)		(2.2)			(2.2)
Shares withheld on vesting of restricted shares (in shares)					(100,000)
Common stock issued under employee stock purchase plan	3.8		3.8			3.8
Common stock issued under employee stock purchase plan (in shares)					300,000
Share-based compensation	15.2		15.2			15.2
Unrealized and realized loss (gain) on forward contracts	0.1		0.1					0.1
Unrealized loss (gain) on change in fair value of available-for-sale securities	0.1		0.1					0.1
Unrealized loss (gain) on defined benefit obligations, net of tax	0.0
Business acquisitions	0.7										0.7
Foreign currency translation adjustments	(1.9)		(1.9)					(1.9)
Other	(0.4)										(0.4)
Balance at ending of period at Sep. 27, 2024	$ 549.2		$ 535.1		$ 0.4	$ 467.2		$ (2.9)	$ 70.4		$ 14.1
Shares outstanding, end of period (in shares) at Sep. 27, 2024	41,094,179				41,100,000